Healthcare & Medical Devices Global On demand · 24-48h

Global Prenatal Testing and Newborn Screening Service Market Strategic Research Report

Global Prenatal Testing and Newborn Screening Service Market…
$3,500 USD
Market Research Reports
Strategic Research Report
Global Prenatal Testing and Newborn Screening Service Market
$5.84B2025
10.5%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Prenatal Testing, Newborn Screening

By Application: Public Hospitals, Private Hospitals, Others

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: Thermo Fisher Scientific, Revvity, Quest Diagnostics, Labcorp, MedGenome, Mayo Clinic Laboratories, GeneDx, PreventionGenetics, SYNLAB, Illumina, Cordlife, KingMed Diagnostics, BGI Genomics, Berry Genomics, Annaroad, Jiajian Medical Testing, Genesky, Weihansi Biomedical Technology

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 133 pages
Market size 2025
$5.84B
Billion USD
Forecast CAGR
10.5%
2025-2032
Forecast 2032
$11.7B
Projected
リージョン
5
Asia Pacific · Latin America · MEA · Europe · North America

概観

Scope of the Report

The global Prenatal Testing and Newborn Screening Service market size is predicted to grow from US$ 5,844 million in 2025 to US$ 11,641 million in 2032; it is expected to grow at a CAGR of 10.5% from 2026 to 2032.

Prenatal Testing and Newborn Screening Service refers to the coordinated clinical services that assess genetic and congenital health risks before birth and identify serious conditions in infants shortly after delivery. It encompasses prenatal risk screening and diagnostic testing during pregnancy, systematic screening of newborns after birth, interpretation and communication of results, confirmatory testing when abnormalities are detected, and referral into timely treatment and long term follow up care.

The prenatal testing and newborn screening service market represents an integrated early life diagnostics segment where clinical value is tightly linked to timing, accuracy, and continuity of care rather than discretionary utilization. Demand is structurally stable because services are embedded in routine obstetric and neonatal care, while competitive dynamics are shaped by regulatory oversight, clinical guidelines, and payer frameworks. The market favors service providers that can operate across the full continuum from prenatal risk assessment to postnatal screening and follow up, as this integration reduces fragmentation and improves clinical decision making. Growth is driven less by volume expansion and more by qualitative upgrades such as broader test menus, improved turnaround time, digital reporting, and coordinated care pathways, reinforcing a market profile that is policy influenced, quality sensitive, and resistant to rapid commoditization.

This report presents a comprehensive overview of the global Prenatal Testing and Newborn Screening Service market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • Prenatal Testing
  • Newborn Screening

Segment by Screening Purpose

  • Core Condition Screening
  • Expanded Condition Screening

Segment by Service Model

  • Public Health Program
  • Consumer
  • Others

Segment by Application

  • Public Hospitals
  • Private Hospitals
  • Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Prenatal Testing and Newborn Screening Service market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Public Hospitals, Private Hospitals, Others evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Prenatal Testing and Newborn Screening Service Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 10.5%
Regional growth momentum
Market share by segment
Key metrics
Base value
$5.84B
2025
Forecast
$11.7B
2032
CAGR
10.5%
2025–2032
リージョン
5
global
Key companies
Thermo Fisher ScientificRevvityQuest DiagnosticsLabcorpMedGenomeMayo Clinic LaboratoriesGeneDxPreventionGenetics
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
Prenatal TestingNewborn Screening
By Application
Public HospitalsPrivate HospitalsOthers

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Prenatal Testing
  • 3.1.3 Newborn Screening
  • 3.1.4 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Public Hospitals
  • 4.1.3 Private Hospitals
  • 4.1.4 Others
  • 4.1.5 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 Thermo Fisher Scientific
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 Revvity
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 Quest Diagnostics
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 Labcorp
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 MedGenome
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 Mayo Clinic Laboratories
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 GeneDx
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 PreventionGenetics
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 SYNLAB
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 Illumina
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
  • 8.11 Cordlife
  • 8.11.1 Company Overview
  • 8.11.2 Key Products & Segments
  • 8.11.3 Financial Performance (2023–2025)
  • 8.11.4 Business Strategy
  • 8.11.5 SWOT Analysis
  • 8.11.6 Strategic Implications (2026–2032)
  • 8.12 KingMed Diagnostics
  • 8.12.1 Company Overview
  • 8.12.2 Key Products & Segments
  • 8.12.3 Financial Performance (2023–2025)
  • 8.12.4 Business Strategy
  • 8.12.5 SWOT Analysis
  • 8.12.6 Strategic Implications (2026–2032)
  • 8.13 BGI Genomics
  • 8.13.1 Company Overview
  • 8.13.2 Key Products & Segments
  • 8.13.3 Financial Performance (2023–2025)
  • 8.13.4 Business Strategy
  • 8.13.5 SWOT Analysis
  • 8.13.6 Strategic Implications (2026–2032)
  • 8.14 Berry Genomics
  • 8.14.1 Company Overview
  • 8.14.2 Key Products & Segments
  • 8.14.3 Financial Performance (2023–2025)
  • 8.14.4 Business Strategy
  • 8.14.5 SWOT Analysis
  • 8.14.6 Strategic Implications (2026–2032)
  • 8.15 Annaroad
  • 8.15.1 Company Overview
  • 8.15.2 Key Products & Segments
  • 8.15.3 Financial Performance (2023–2025)
  • 8.15.4 Business Strategy
  • 8.15.5 SWOT Analysis
  • 8.15.6 Strategic Implications (2026–2032)
  • 8.16 Jiajian Medical Testing
  • 8.16.1 Company Overview
  • 8.16.2 Key Products & Segments
  • 8.16.3 Financial Performance (2023–2025)
  • 8.16.4 Business Strategy
  • 8.16.5 SWOT Analysis
  • 8.16.6 Strategic Implications (2026–2032)
  • 8.17 Genesky
  • 8.17.1 Company Overview
  • 8.17.2 Key Products & Segments
  • 8.17.3 Financial Performance (2023–2025)
  • 8.17.4 Business Strategy
  • 8.17.5 SWOT Analysis
  • 8.17.6 Strategic Implications (2026–2032)
  • 8.18 Weihansi Biomedical Technology
  • 8.18.1 Company Overview
  • 8.18.2 Key Products & Segments
  • 8.18.3 Financial Performance (2023–2025)
  • 8.18.4 Business Strategy
  • 8.18.5 SWOT Analysis
  • 8.18.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

What is the current global Prenatal Testing and Newborn Screening Service market size?
The global Prenatal Testing and Newborn Screening Service market is estimated at US$ 5.84 billion in 2025 (base year) and is projected to reach US$ 11.64 billion by 2032.
What growth rate is expected for the Prenatal Testing and Newborn Screening Service market through 2032?
The market is expected to grow at a CAGR of 10.5% from 2026 to 2032, expanding from US$ 5.84 billion in 2025 to US$ 11.64 billion in 2032, roughly 2.0 times its base-year value.
How is Prenatal Testing and Newborn Screening Service defined?
Prenatal Testing and Newborn Screening Service refers to the coordinated clinical services that assess genetic and congenital health risks before birth and identify serious conditions in infants shortly after delivery. It encompasses prenatal risk screening and diagnostic testing during pregnancy, systematic screening of newborns after birth, interpretation and communication of results, confirmatory testing when abnormalities are detected, and referral into timely treatment and long term follow up care.
What are the main segments of the Prenatal Testing and Newborn Screening Service market by type?
By type, the market is segmented into Prenatal Testing and Newborn Screening.
Which applications drive demand in the Prenatal Testing and Newborn Screening Service market?
Key applications covered include Public Hospitals, Private Hospitals and Others.
Who are the key players in the Prenatal Testing and Newborn Screening Service market?
Key players profiled include Thermo Fisher Scientific, Revvity, Quest Diagnostics, Labcorp, MedGenome, Mayo Clinic Laboratories, GeneDx and PreventionGenetics, among 18 companies covered in total.
Which regions and countries are covered for Prenatal Testing and Newborn Screening Service?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
What is driving growth in the Prenatal Testing and Newborn Screening Service market?
Growth is driven less by volume expansion and more by qualitative upgrades such as broader test menus, improved turnaround time, digital reporting, and coordinated care pathways, reinforcing a market profile that is policy influenced, quality sensitive, and resistant to rapid commoditization.
Who should buy the Prenatal Testing and Newborn Screening Service market report?
The report is intended for manufacturers and solution providers, distributors and end users in Public Hospitals, Private Hospitals and Others, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Prenatal Testing and Newborn Screening Service market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

Select a license
from $3,500.00
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.